Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
Back to dashboard
Company Information
About this company
Key people
Maria C. Freire
Independent Chairman of the Board
Sean Godbout
Chief Accounting Officer, Vice President, Global Corporate Controller, Principal Accounting Officer
William A. Hawkins
Independent Director
Susan Langer
Independent Director
Jesus B. Mantas
Independent Director
Lloyd B. Minor
Independent Director
Christopher A. Viehbacher
President, Chief Executive Officer, Director
Robin C. Kramer
Chief Financial Officer, Executive Vice President
Ginger Gregory
Chief Human Resources Officer, Executive Vice President
Jane Grogan
Executive Vice President, Head of Research
Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Adam James Keeney
Executive Vice President, Head of Corporate Development
Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Priya Singhal
Executive Vice President, Head of Development
Click to see more
Key facts
- Shares in issue171.55m
- EPICBIIB
- ISINUS09062X1037
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$34.40bn
- Employees7,500
- ExchangeNASDAQ
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.